- Home
- NTLA
as 07-05-2024 4:00pm EST
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.5B | IPO Year: | 2016 |
| Target Price: | $66.93 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.37 - $46.50 | Next Earning Date: | 08-01-2024 |
| Revenue: | $52,604,000 | Revenue Growth: | -1.63% |
| Revenue Growth (this year): | 99.04% | Revenue Growth (next year): | -4.10% |
Stock Insider Trading Activity of Intellia Therapeutics Inc. (NTLA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Verwiel Frank | NTLA | Director | Jun 17 '24 | Sell | $25.00 | 1,505 | $37,625.00 | 17,948 | SEC Form 4 |
| Clark Eliana | NTLA | EVP, Chief Technical Officer | Mar 1 '24 | Sell | $32.99 | 605 | $19,958.95 | 71,470 | SEC Form 4 |
| BASTA JAMES | NTLA | EVP, General Counsel | Mar 1 '24 | Sell | $32.99 | 2,297 | $75,778.03 | 81,571 | SEC Form 4 |
| Sepp-Lorenzino Laura | NTLA | EVP, Chief Scientific Officer | Jan 8 '24 | Sell | $28.66 | 1,608 | $46,085.28 | 44,594 | SEC Form 4 |
| Sepp-Lorenzino Laura | NTLA | EVP, Chief Scientific Officer | Jan 8 '24 | Sell | $29.38 | 667 | $19,596.46 | 43,927 | SEC Form 4 |
| BASTA JAMES | NTLA | EVP, General Counsel | Jan 3 '24 | Sell | $29.46 | 3,805 | $112,095.30 | 51,474 | SEC Form 4 |
| Lebwohl David | NTLA | EVP, Chief Medical Officer | Jan 3 '24 | Sell | $29.46 | 5,843 | $172,134.78 | 54,372 | SEC Form 4 |
| Clark Eliana | NTLA | EVP, Chief Technical Officer | Jan 3 '24 | Sell | $30.12 | 307 | $9,246.84 | 45,146 | SEC Form 4 |
| Clark Eliana | NTLA | EVP, Chief Technical Officer | Jan 3 '24 | Sell | $29.46 | 4,301 | $126,707.46 | 40,845 | SEC Form 4 |
| LEONARD JOHN M | NTLA | President and CEO | Jan 3 '24 | Sell | $29.46 | 19,223 | $566,309.58 | 846,486 | SEC Form 4 |
| Goddard Glenn | NTLA | EVP, Chief Financial Officer | Jan 3 '24 | Sell | $29.46 | 5,365 | $158,052.90 | 40,585 | SEC Form 4 |
| Hicks Derek | NTLA | EVP, Chief Business Officer | Jan 3 '24 | Sell | $29.46 | 3,877 | $114,216.42 | 36,987 | SEC Form 4 |
| Sepp-Lorenzino Laura | NTLA | EVP, Chief Scientific Officer | Jan 3 '24 | Sell | $29.46 | 5,532 | $162,972.72 | 46,202 | SEC Form 4 |
Latest Intellia Therapeutics Inc. News
NTLA Breaking Stock News: Dive into NTLA Ticker-Specific Updates for Smart Investing
Motley Fool
5 days ago
3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024
Zacks
10 days ago
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
MT Newswires
11 days ago
Intellia Therapeutics Names Edward Dulac CFO
GlobeNewswire
11 days ago
Intellia Therapeutics Announces CFO Transition
BioPharma Dive
11 days ago
First-of-its-kind Intellia data suggest CRISPR drug could be given more than once
GlobeNewswire
11 days ago
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
GlobeNewswire
20 days ago
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
Zacks
23 days ago
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Share on Social Networks:
Disclaimer
The information presented on this page, "NTLA Intellia Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.